EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas

Raphael Labens iD, Corey Saba iD, Jarred Williams iD, Anna Hollis iD, Jos Ensink, Eduard Jose-Cunilleras, Mireia Jordana-Garcia, Kerstin Bergvall iD, Mick Ruppin, Frank Condon, Caroline Spelta, Yvonne Elce iD und 4 weitere

Equine Veterinary Journal · 2026

DOI: 10.1111/evj.14502 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Equine Veterinary Journal, 2026. Verfasst von Raphael Labens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Charles Sturt University, Wagga Wagga, New South Wales, Australia. Hauptthemen laut MEDLINE: Horse Diseases, Skin Neoplasms, Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: QBiotics Group Limited, Qbiotics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intralesional chemotherapeutic administration represents an important treatment option for equine cutaneous neoplasia. Tigilanol‐tiglate (TT), a novel molecule extracted from Fontainea picrosperma , an Australian rainforest plant, is registered for intratumoural treatment of canine MCT, leading to rapid oncosis and tumour slough. Evidence from horses is limited but suggests that efficacy may be similar.

Objectives

To evaluate the response to intratumoural TT treatment in horses with sarcoids (fibroblastic/nodular) and cutaneous melanomas. Study Design Two noncontrolled prospective multicentre clinical trials, one for each of sarcoids and melanomas.

Methods

Cases were enrolled across multiple sites and treated by the same site‐specific clinician with intralesional TT (sarcoids: 0.35 mg/cm 3 ; melanomas: 0.2 mg/cm 3 of tumour volume − T vol ; max dose 2 mg). Quantitative ( T vol regression) and qualitative outcomes (likely tumour free (LTF) per expert opinion) were recorded, and potential determinants of efficacy were assessed using random effects logistic models. A full clinical response was complete T vol regression and a LTF treatment site.

Results

Forty‐one sarcoids and 97 melanomas were enrolled and treated. 73/74% of treated sarcoids/melanomas showed complete T vol regression. 64/61% (sarcoids/melanomas) showed a full clinical response at medians of 546/247 days post final treatment. For both tumour types, this response was dependent on initial tumour volume ( P sarcoids = 0.006; P melanomas

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Horse DiseasesSkin NeoplasmsMelanomaAntineoplastic AgentsAnimalsHorsesFemaleMaleProspective StudiesInjections, Intralesional

Stichwörter der Autor:innen

horseneoplasiaskinstelfonta

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • University of Georgia, Athens, Georgia, USA.
  • University of Cambridge, Cambridge, UK.
  • Utrecht University, Utrecht, The Netherlands.
  • Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Swedish University of Agricultural Sciences, Uppsala, Sweden.

ORCID-Profile: Raphael Labens, Corey Saba, Jarred Williams, Anna Hollis, Kerstin Bergvall, Yvonne Elce, Thomas De Ridder, Paul Reddell

Förderung

  • QBiotics Group Limited
  • Qbiotics

Zitieren

APA

Labens, R., Saba, C., Williams, J., Hollis, A., Ensink, J., Jose-Cunilleras, E., Jordana-Garcia, M., Bergvall, K., Ruppin, M., Condon, F., Spelta, C., Elce, Y., De Ridder, T., Morton, J., McGee, C., & Reddell, P. (2026). Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Veterinary Journal. https://doi.org/10.1111/evj.14502

Vancouver

Labens R, Saba C, Williams J, Hollis A, Ensink J, Jose-Cunilleras E, et al. Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Veterinary Journal. 2026. doi:10.1111/evj.14502

BibTeX
@article{Labens2026,
  author = {Labens, Raphael and Saba, Corey and Williams, Jarred and Hollis, Anna and Ensink, Jos and Jose-Cunilleras, Eduard and Jordana-Garcia, Mireia and Bergvall, Kerstin and Ruppin, Mick and Condon, Frank and Spelta, Caroline and Elce, Yvonne and De Ridder, Thomas and Morton, John and McGee, Cassandra and Reddell, Paul},
  title = {Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas},
  journal = {Equine Veterinary Journal},
  year = {2026},
  doi = {10.1111/evj.14502}
}
Kostenlos starten →